Latest News

In Memoriam of Jelle Palsma

It is with great sadness that we share with you that our friend and colleague, Jelle Palsma passed away. Jelle was part of the board of MPE’s French member, Association Française des Malades du Myélome Multiple (AF3M), and was a very active representative at MPE. Despite his health condition, Jelle was involved in highly relevant Read the full article…

Myeloma highlights at EHA 2017

The most important Haematology scientific meeting in Europe, the European Hematology Association (EHA) Annual Meeting was held between 22 and 25 June 2017 in Madrid (Spain). The impact of cytogenetic analysis in myeloma as an important genetic risk factor, updated results on the Pollux and Castor prospective clinical trials including daratumumab in triplet combination of Read the full article…

Promising results of CAR T-Cell therapy in myeloma patients

53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) CHICAGO – In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of myeloma upon receiving a new type of immunotherapy  ̶  chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. Most patients had only mild side effects. The study was presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Read the full article…

In Memoriam of Yacob Yacobovitch

We all were saddened to hear of our recent loss of Yacob Yacobovitch, who passed away on the 18th of april 2017. Yacob Yacobovitch was member of Myeloma Patients Europe from 2012 until 2016. He was a friendly and charismatic person, a very respected patient advocate of our member patient organisation Amen of Israel. In Read the full article…

European Commission (EC) extends approval for daratumumab to include myeloma patients who have received at least one prior therapy

European Commission (EC) has granted approval daratumumab for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with myeloma who have received at least one prior therapy. The EC’s decision was based on data from the Phase 3 POLLUX (MMY3003) study, presented at ASCO 2016 and published Read the full article…

MPE Advocate Development Programme (ADP)

The MPE Advocate Development Programme (ADP) is a training programme directed to MPE members with the aim to provide them with the skills and knowledge that any myeloma patient advocate should have regarding the drug development process. The main goal of MPE is to put medicines research into a myeloma context and create a tailored Read the full article…